Title

SGLT2 inhibitors - moving on with the evidence.

Authors

Morris, David

Abstract

The evidence base on the benefits and risks of using sodium-glucose cotransporter 2 (SGLT2) inhibitors for the management of hyperglycaemia has grown in recent years, with data showing potential cardiovascular and renal benefits, along with safety concerns that warrant cautious use and monitoring in certain users. This article reviews the benefits and difficulties associated with the use of SGLT2 inhibitors in people with type 2 diabetes and, potentially, type 1 diabetes.

Subjects

AMPUTATION; DIABETIC acidosis; BONE fractures; GENITOURINARY organs; TYPE 1 diabetes; MEDICAL protocols; TYPE 2 diabetes; PATIENT education; EVIDENCE-based medicine; FOURNIER gangrene; DISEASE risk factors; SODIUM-glucose cotransporters; THERAPEUTICS

Publication

Journal of Diabetes Nursing, 2019, Vol 23, Issue 4, p1

ISSN

1368-1109

Publication type

Academic Journal